HC Wainwright Has Positive Forecast for SLNO FY2025 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Equities researchers at HC Wainwright upped their FY2025 earnings estimates for Soleno Therapeutics in a research report issued on Tuesday, January 20th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.42 for the year, up from their prior estimate of $0.10. HC Wainwright currently has a “Buy” rating and a $120.00 price objective on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics’ Q4 2025 earnings at $0.83 EPS, Q1 2026 earnings at $0.88 EPS and FY2026 earnings at $4.82 EPS.

A number of other research firms have also weighed in on SLNO. Wall Street Zen upgraded shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Zacks Research upgraded shares of Soleno Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. The Goldman Sachs Group set a $125.00 price objective on shares of Soleno Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 7th. Wolfe Research set a $60.00 price objective on Soleno Therapeutics in a research report on Monday, January 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Soleno Therapeutics has a consensus rating of “Buy” and an average price target of $110.62.

Soleno Therapeutics Price Performance

SLNO opened at $42.36 on Thursday. The firm has a market cap of $2.28 billion, a PE ratio of -23.02 and a beta of -3.12. The stock has a 50-day moving average price of $47.11 and a 200-day moving average price of $61.27. Soleno Therapeutics has a 1 year low of $39.43 and a 1 year high of $90.32. The company has a debt-to-equity ratio of 0.10, a current ratio of 16.08 and a quick ratio of 15.88.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.39. The company had revenue of $66.02 million during the quarter, compared to the consensus estimate of $47.46 million.

Institutional Investors Weigh In On Soleno Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. bought a new position in shares of Soleno Therapeutics during the 2nd quarter valued at $25,000. Danske Bank A S purchased a new stake in Soleno Therapeutics during the third quarter valued at $27,000. Aster Capital Management DIFC Ltd bought a new position in Soleno Therapeutics in the third quarter valued at about $37,000. Nisa Investment Advisors LLC lifted its holdings in Soleno Therapeutics by 287.8% in the second quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock valued at $45,000 after acquiring an additional 400 shares during the period. Finally, Quarry LP purchased a new position in Soleno Therapeutics in the third quarter worth about $47,000. Institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.